{"id":625934,"date":"2022-11-16T18:38:05","date_gmt":"2022-11-16T18:38:05","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=625934"},"modified":"2022-11-16T18:38:05","modified_gmt":"2022-11-16T18:38:05","slug":"adenoassociated-virus-aav-vectorbased-gene-therapy-market-size-epidemiology-therapies-treatment-landscape-and-patient-data-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/adenoassociated-virus-aav-vectorbased-gene-therapy-market-size-epidemiology-therapies-treatment-landscape-and-patient-data-by-delveinsight_625934.html","title":{"rendered":"Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, Epidemiology, Therapies, Treatment landscape and Patient data by DelveInsight"},"content":{"rendered":"
\n
\"Adeno-Associated<\/a><\/div>\n
\n
Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market<\/div>\n<\/div>\n<\/div>\n

(Albany, US) DelveInsight’s “Adeno-Associated Virus Vectors in Gene Therapy Market Insights, Epidemiology, and Market Forecast-2032″<\/strong> report delivers an in-depth understanding of the Adeno-Associated Virus Vectors in Gene Therapy, historical and forecasted epidemiology as well as the Adeno-Associated Virus Vectors in Gene Therapy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

 <\/strong><\/p>\n

Some facts of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy report:<\/strong><\/p>\n

    \n
  1. The AAV based gene therapies market size in the United States was valued to be USD 428 million in 2019.<\/li>\n
  2. In the year 2020, the total prevalent cases of selected indications for AAV Gene Therapies were 2,863,103 in the 7MM.<\/li>\n
  3. In EU-5 countries the highest number of prevalent cases were in Germany, i.e., 441,670 in the year 2020.<\/li>\n
  4. The total prevalent cases of Hemophilia A and Hemophilia B were reported to be 43,243 and 10,811 in 2020.<\/li>\n
  5. In the United Kingdom, the total treated cases of Parkinson’s disease and Spinal Muscular Atrophy were 32,255 and 949, respectively, in the year 2020.<\/li>\n<\/ol>\n

     <\/strong><\/p>\n

    Get more comprehensive insights into how Adeno-Associated Virus (AAV) Vector-Based Gene Therapy epidemiological trends are impacting current and forecasted Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market @  Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Epidemiology Analysis and Forecast<\/a><\/strong><\/p>\n

     <\/strong><\/p>\n

    Key Benefits of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report:<\/strong><\/p>\n